Ionis Pharmaceuticals Inc IONS
We take great care to ensure that the data presented and summarized in this overview for IONIS PHARMACEUTICALS INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding IONS
View all-
Vanguard Group Inc Valley Forge, PA15.1MShares$576 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD14.2MShares$542 Million0.34% of portfolio
-
Black Rock Inc. New York, NY10.3MShares$395 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA8.74MShares$334 Million0.06% of portfolio
-
Bellevue Group Ag Kuesnacht, V87.87MShares$301 Million5.32% of portfolio
-
Capital World Investors Los Angeles, CA7.83MShares$300 Million0.05% of portfolio
-
State Street Corp Boston, MA4.85MShares$186 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.21MShares$161 Million0.02% of portfolio
-
Tweedy Browne Co. Tweedy, Browne CO LLC | Stamford, Ct3.45MShares$132 Million6.83% of portfolio
-
Pictet Asset Management Sa Geneva 73, V83.1MShares$118 Million0.15% of portfolio
Latest Institutional Activity in IONS
Top Purchases
Top Sells
About IONS
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.
Insider Transactions at IONS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 12
2024
|
Joseph Loscalzo Director |
SELL
Open market or private sale
|
Direct |
13,508
-29.52%
|
$499,796
$37.86 P/Share
|
|
Nov 12
2024
|
Brett P Monia Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
6,630
-3.81%
|
$251,940
$38.05 P/Share
|
|
Nov 12
2024
|
Eric Swayze EVP Research |
SELL
Open market or private sale
|
Direct |
1,194
-3.42%
|
$44,178
$37.92 P/Share
|
|
Oct 16
2024
|
Eric Swayze EVP Research |
SELL
Open market or private sale
|
Indirect |
53
-25.24%
|
$2,014
$38.31 P/Share
|
|
Oct 15
2024
|
Eric Swayze EVP Research |
BUY
Exercise of conversion of derivative security
|
Indirect |
125
+37.31%
|
-
|
|
Aug 30
2024
|
Eric Swayze EVP Research |
BUY
Other acquisition or disposition
|
Direct |
11
+0.03%
|
$418
$38.64 P/Share
|
|
Aug 30
2024
|
C Frank Bennett EVP, Chief Scientific Officer |
BUY
Other acquisition or disposition
|
Direct |
177
+0.22%
|
$6,726
$38.64 P/Share
|
|
Aug 30
2024
|
Brian Birchler EVP, Corp and Development Ops |
BUY
Other acquisition or disposition
|
Direct |
12
+0.03%
|
$456
$38.64 P/Share
|
|
Aug 30
2024
|
Richard S Geary EVP, Chief Development Officer |
BUY
Other acquisition or disposition
|
Direct |
11
+0.01%
|
$418
$38.64 P/Share
|
|
Aug 30
2024
|
Brett P Monia Chief Executive Officer |
BUY
Other acquisition or disposition
|
Direct |
140
+0.08%
|
$5,320
$38.64 P/Share
|
|
Aug 30
2024
|
Patrick R. O'Neil EVP CLO & General Counsel |
BUY
Other acquisition or disposition
|
Direct |
246
+0.5%
|
$9,348
$38.64 P/Share
|
|
Aug 29
2024
|
Richard S Geary EVP, Chief Development Officer |
SELL
Open market or private sale
|
Direct |
331
-0.39%
|
$16,219
$49.63 P/Share
|
|
Aug 28
2024
|
Richard S Geary EVP, Chief Development Officer |
SELL
Open market or private sale
|
Direct |
320
-0.37%
|
$15,680
$49.16 P/Share
|
|
Aug 05
2024
|
Richard S Geary EVP, Chief Development Officer |
SELL
Open market or private sale
|
Direct |
2,430
-2.76%
|
$116,640
$48.0 P/Share
|
|
Jul 16
2024
|
Allene M. Diaz Director |
SELL
Open market or private sale
|
Direct |
1,637
-4.83%
|
$80,213
$49.55 P/Share
|
|
Jul 16
2024
|
Joseph Klein Iii Director |
SELL
Open market or private sale
|
Indirect |
12,000
-100.0%
|
$600,000
$50.0 P/Share
|
|
Jul 16
2024
|
Joseph Klein Iii Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
12,000
+50.0%
|
$288,000
$24.42 P/Share
|
|
Jul 15
2024
|
Spencer R Berthelsen Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,677
+2.99%
|
-
|
|
Jul 15
2024
|
Allene M. Diaz Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,677
+21.23%
|
-
|
|
Jul 15
2024
|
Joan E Herman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,677
+10.02%
|
-
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 668K shares |
|---|---|
| Grant, award, or other acquisition | 73.1K shares |
| Other acquisition or disposition | 3.33K shares |
| Open market or private sale | 522K shares |
|---|---|
| Payment of exercise price or tax liability | 54.8K shares |